Observation on the clinical efficacy of high-intensity focused ultrasound ablation combined with gonadotropin-releasing hormone agonist in the treatment of hysteromyoma
Objective:To compare the therapeutic effects and safety of high-intensity focused ultrasound(HIFU)alone and HIFU combined with gonadotropin releasing hormone agonist(GnRH-a)in the treatment of uterine fibroids.Methods:A retrospective analysis was conducted on the clinical data of 120 patients with uterine fibroids who received HIFU treatment.Among them,36 cases underwent pre-treatment of GnRH-a combined with HIFU(group A),and 19 cases were treated with GnRH-a after HIFU treatment(group B),65 cases were treated with HIFU alone(group C).Uterine fibroid volume,uterine fibroid symptom score,and hemoglobin(Hb)levels were assessed at 1,6,and 12 months after HIFU.Results:There were no significant differences in the age,body mass index and the volume of uterine fibroids among the three groups(P＞0.05).The total therapeutic energy of group A was significantly lower than that of group B(P＜0.05).After treatment,the volume of uterine fibroids in the three groups significantly decreased(P＜0.05),the symptom score of uterine fibroids significantly decreased(P＜0.05),and the Hb level significantly increased(P＜0.05).One month after HIFU,there were no statistically significant differences in uterine fibroid symptom scores and Hb levels among the three groups(P＞0.05).However,at 6 and 12 months after HIFU,the symptom scores of uterine fibroids in group A and B were significantly lower than that of group C(P＜0.05),while Hb levels were significantly higher(P＜0.05).At 12 months after HIFU,four patients in group C,while none in group A and B,experienced recurrence.No serious adverse reactions were found in the three groups.Conclusions:HIFU combined with GnRH-a can be effectively and safely applied in the treatment of uterine fibroids with the trend of higher symptom relief and uterine fibroid reduction rates as well as lower recurrence rate.
万方数据
维普
